Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

GSK completes acquisition of Reliant and obtains U.S. and Porto Rican rights to Lovaza

Dec. 27, 2007

New therapeutic approach for inherited form of hypoparathyroidism

Dec. 24, 2007

Raptor acquires exclusive worldwide license to EC Cysteamine for nephropathic cystinosis

Dec. 24, 2007

New agents for treating diabetes disclosed in recent patent literature

Dec. 24, 2007

GSK submits NDA to FDA for Promacta for idiopathic thrombocytopenic purpura

Dec. 21, 2007

AMAG Pharmaceuticals submits NDA to FDA for ferumoxytol for chronic kidney disease

Dec. 21, 2007

Biovitrum successfully completes phase I BVT-74316 study

Dec. 20, 2007

DiaMedica receives Polish regulatory clearance for phase II human study of DM-83

Dec. 20, 2007

Wyeth Pharmaceuticals submits clinical study reports of Viviant to supplement pending NDA

Dec. 20, 2007

Recent patents report new antiobesity agents

Dec. 20, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...